Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

Fig. 3

CXCL4 levels decreased significantly in response to immunosuppression in each treatment arm from baseline to 12 months (CYC: P < 0.001; MMF: P = 0.006) and from baseline to 24 months (CYC: P < 0.001; MMF: P = 0.011). There was no between-treatment difference in the reduction in CXCL4 from baseline to 12 months or from baseline to 24 months. CYC cyclophosphamide, MMF mycophenolate

Back to article page